{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:09:37Z","timestamp":1793840977946,"version":"4.6.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Herzzentrum G\u00f6ttingen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Standard treatment for unresectable stage III non-small cell lung cancer (NSCLC) involves chemoradiation (CRT) followed by PD-L1 targeting immune checkpoint inhibition (IO). Integrating 18\u00a0F-fluorodeoxyglucose-positron emission tomography (FDG-PET)\/CT into radiotherapy planning reduces toxicity, improves CRT outcomes, and potentially enhances immunotherapy response. Hypofractionated, accelerated CRT shortens treatment time, improves compliance, and may increase CRT completion rates, qualifying more patients for consolidative IO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/design<\/jats:title>\n                    <jats:p>PACCELIO is a multinational, multicenter, randomized, phase II trial comparing the safety and efficacy of FDG-PET\/CT based, volume-reduced, hypofractionated CRT with consolidation durvalumab to standard-volume, conventionally fractionated CRT with consolidation durvalumab in inoperable stage III NSCLC. One hundred and ten patients will be enrolled in Germany, Austria, and Switzerland, randomized 1:1, stratified by age, NSCLC stage, and site. The primary objective is to increase completion of CRT with successful transition to consolidation immunotherapy. Secondary outcomes include locoregional and distant tumor control rates, overall survival, safety, and health-related quality of life (HR-QoL). Exploratory outcomes involve prognostic immunomarkers and PET parameters. The primary endpoint of treatment completion will be analyzed using Fisher's Exact test, with safety and efficacy outcomes analyzed via Kaplan-Meier.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The PACCELIO trial addresses a clinical need in stage III NSCLC by combining FDG-PET\/CT based RT volume reduction with hypofractionated accelerated CRT and durvalumab immunotherapy. This approach aims to improve treatment completion, compliance, tumor control, and reduce toxicity. The trial will provide insights into the efficacy and safety of this combined treatment, potentially influencing future standards in stage III NSCLC treatment. Recruitment began in July 2024, with ongoing enrollment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Clinicaltrials.gov identifier: NCT06102057 (Date of initial registration: 26th October 2023),\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT06102057\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT06102057<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15901-x","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T02:14:27Z","timestamp":1776392067000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["FDG-PET\/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) \u2013 a randomized, open-label, multicenter phase II trial protocol"],"prefix":"10.1186","volume":"26","author":[{"given":"Rami El","family":"Shafie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Willmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Gkika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Schimek-Jasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Miederer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farastuk","family":"Bozorgmehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farkhad","family":"Manapov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"B\u00fctof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Schmid-Bindert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Meiners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Herzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Lamch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Nestle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"3","key":"15901_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"15901_CR2","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S1470-2045(23)00444-8","volume":"24","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Vaccarella S, Morgan E, Li M, Etxeberria J, Chokunonga E, Manraj SS, Kamate B, Omonisi A, Bray F. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. Lancet Oncol. 2023;24(11):1206\u201318.","journal-title":"Lancet Oncol"},{"key":"15901_CR3","doi-asserted-by":"publisher","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919\u20131929. https:\/\/doi.org\/10.1056\/NEJMoa1709937. Epub\u00a08\u00a0Sept 2017. PMID: 28885881.","DOI":"10.1056\/NEJMoa1709937"},{"key":"15901_CR4","doi-asserted-by":"publisher","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301\u20131311. https:\/\/doi.org\/10.1016\/S1470-2045(20)30013-9. Epub 2 Feb 2022. Erratum in: J Clin Oncol. 2022;40(17):1965. https:\/\/doi.org\/10.1200\/JCO.22.01023. PMID: 35108059; PMCID: PMC9015199.","DOI":"10.1016\/S1470-2045(20)30013-9"},{"issue":"2","key":"15901_CR5","doi-asserted-by":"publisher","first-page":"100410","DOI":"10.1016\/j.esmoop.2022.100410","volume":"7","author":"S Senan","year":"2022","unstructured":"Senan S, Ozguroglu M, Daniel D, Villegas A, Vicente D, Murakami S, Hui R, Faivre-Finn C, Paz-Ares L, Wu YL, Mann H, Dennis PA, Antonia SJ. Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. ESMO Open. 2022;7(2):100410.","journal-title":"ESMO Open"},{"issue":"12","key":"15901_CR6","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","volume":"32","author":"J Remon","year":"2021","unstructured":"Remon J, Soria JC, Peters S. clinicalguidelines@esmo.org EGCEa. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637\u201342.","journal-title":"Ann Oncol"},{"key":"15901_CR7","doi-asserted-by":"publisher","unstructured":"Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187\u201399. https:\/\/doi.org\/10.1016\/S1470-2045(14)71207-0. Epub 2015 Jan 16. PMID: 25601342; PMCID: PMC4419359.","DOI":"10.1016\/S1470-2045(14)71207-0"},{"key":"15901_CR8","doi-asserted-by":"publisher","unstructured":"Aup\u00e9rin A, Le P\u00e9choux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181\u201390. https:\/\/doi.org\/10.1200\/JCO.2009.26.2543 29","DOI":"10.1200\/JCO.2009.26.2543"},{"key":"15901_CR9","doi-asserted-by":"publisher","unstructured":"Eichkorn T, Bozorgmehr F, Regnery S, Dinges LA, Kudak A, Bougatf N, et al. Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration Rates. Front Oncol. 2020;10:586449. https:\/\/doi.org\/10.3389\/fonc.2020.586449. PMID: 33335856; PMCID: PMC7736629.","DOI":"10.3389\/fonc.2020.586449"},{"issue":"4","key":"15901_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/COC.0000000000000899","volume":"45","author":"AK Bryant","year":"2022","unstructured":"Bryant AK, Yin H, Schipper MJ, Paximadis PA, Boike TP, Bergsma DP, Movsas B, Dess RT, Mietzel MA, Kendrick R, Seferi M, Dominello MM, Matuszak MM, Jagsi R, Hayman JA, Pierce LJ, Jolly S. Michigan radiation oncology quality c. uptake of adjuvant durvalumab after definitive concurrent chemoradiotherapy for stage III non small-cell lung cancer. Am J Clin Oncol. 2022;45(4):142\u20135.","journal-title":"Am J Clin Oncol"},{"key":"15901_CR11","doi-asserted-by":"publisher","first-page":"744956","DOI":"10.3389\/fonc.2021.744956","volume":"11","author":"A Bruni","year":"2021","unstructured":"Bruni A, Scotti V, Borghetti P, Vagge S, Cozzi S, D\u2019Angelo E, Giaj Levra N, Fozza A, Taraborrelli M, Piperno G, Vanoni V, Sepulcri M, Trovo M, Nardone V, Lattanzi E, Bou Selman S, Bertolini F, Franceschini D, Agustoni F, Jereczek-Fossa BA, Magrini SM, Livi L, Lohr F, Filippi AR. A real-world, multicenter, observational retrospective study of durvalumab after concomitant or sequential chemoradiation for unresectable stage III non-small cell lung cancer. Front Oncol. 2021;11:744956.","journal-title":"Front Oncol"},{"key":"15901_CR12","doi-asserted-by":"publisher","first-page":"1217424","DOI":"10.3389\/fonc.2023.1217424","volume":"13","author":"CW Langberg","year":"2023","unstructured":"Langberg CW, Horndalsveen H, Helland A, Haakensen VD. Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC. Front Oncol. 2023;13:1217424.","journal-title":"Front Oncol"},{"issue":"2","key":"15901_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","volume":"18","author":"N Girard","year":"2023","unstructured":"Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol. 2023;18(2):181\u201393.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"15901_CR14","doi-asserted-by":"publisher","first-page":"e0314156","DOI":"10.1371\/journal.pone.0314156","volume":"19","author":"A Arunachalam","year":"2024","unstructured":"Arunachalam A, Sura S, Murphy J, Conkling P, Goldschmidt J. Real-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer. PLoS ONE. 2024;19(11):e0314156.","journal-title":"PLoS ONE"},{"issue":"12","key":"15901_CR15","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Ozguroglu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301\u201311.","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"15901_CR16","doi-asserted-by":"publisher","first-page":"S1324","DOI":"10.1245\/s10434-015-4735-5","volume":"22","author":"Y Takahashi","year":"2015","unstructured":"Takahashi Y, Horio H, Hato T, Harada M, Matsutani N, Morita S, Kawamura M. Prognostic significance of preoperative neutrophil-lymphocyte ratios in patients with stage I non-small cell lung cancer after complete resection. Ann Surg Oncol. 2015;22(Suppl 3):S1324\u20131331.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"15901_CR17","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.","journal-title":"J Natl Cancer Inst"},{"key":"15901_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4137\/CMO.S30891","volume":"9","author":"SH Jafri","year":"2015","unstructured":"Jafri SH, Previgliano C, Khandelwal K, Shi R. Cachexia index in advanced non-small-cell lung cancer patients. Clin Med Insights Oncol. 2015;9:87\u201393.","journal-title":"Clin Med Insights Oncol"},{"issue":"5","key":"15901_CR19","doi-asserted-by":"publisher","first-page":"100254","DOI":"10.1016\/j.esmoop.2021.100254","volume":"6","author":"G Mountzios","year":"2021","unstructured":"Mountzios G, Samantas E, Senghas K, Zervas E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, Athanasiadis I, Gaissmaier L, Elshiaty M, Daniello L, Christopoulou A, Pentheroudakis G, Lianos E, Linardou H, Kriegsmann K, Kosmidis P, El Shafie R, Kriegsmann M, Psyrri A, Andreadis C, Fountzilas E, Heussel CP, Herth FJ, Winter H, Emmanouilides C, Oikonomopoulos G, Meister M, Muley T, Bischoff H, Saridaki Z, Razis E, Perdikouri EI, Stenzinger A, Boukovinas I, Reck M, Syrigos K, Thomas M, Christopoulos P. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open. 2021;6(5):100254.","journal-title":"ESMO Open"},{"issue":"4","key":"15901_CR20","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.21037\/tlcr-20-805","volume":"10","author":"U Nestle","year":"2021","unstructured":"Nestle U, Le Pechoux C, De Ruysscher D. Evolving target volume concepts in locally advanced non-small cell lung cancer. Transl Lung Cancer Res. 2021;10(4):1999\u20132010.","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"15901_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/S1470-2045(20)30013-9","volume":"21","author":"U Nestle","year":"2020","unstructured":"Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Kusters A, Tosch M, Hehr T, Eschmann SM, Bultel YP, Hass P, Fleckenstein J, Thieme A, Stockinger M, Dieckmann K, Miederer M, Holl G, Rischke HC, Gkika E, Adebahr S, Konig J, Grosu AL. group PE-Ps. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21(4):581\u201392.","journal-title":"Lancet Oncol"},{"issue":"9","key":"15901_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00066-021-01812-2","volume":"197","author":"C Lapa","year":"2021","unstructured":"Lapa C, Nestle U, Albert NL, Baues C, Beer A, Buck A, Budach V, Butof R, Combs SE, Derlin T, Eiber M, Fendler WP, Furth C, Gani C, Gkika E, Grosu AL, Henkenberens C, Ilhan H, Lock S, Marnitz-Schulze S, Miederer M, Mix M, Nicolay NH, Niyazi M, Pottgen C, Rodel CM, Schatka I, Schwarzenboeck SM, Todica AS, Weber W, Wegen S, Wiegel T, Zamboglou C, Zips D, Zophel K, Zschaeck S, Thorwarth D, Troost EGC. Arbeitsgemeinschaft Nuklearmedizin und Strahlentherapie der DuDGN. Value of PET imaging for radiation therapy. Strahlenther Onkol. 2021;197(9):1\u201323.","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"15901_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","volume":"127","author":"U Nestle","year":"2018","unstructured":"Nestle U, De Ruysscher D, Ricardi U, Geets X, Belderbos J, Pottgen C, Dziadiuszko R, Peeters S, Lievens Y, Hurkmans C, Slotman B, Ramella S, Faivre-Finn C, McDonald F, Manapov F, Putora PM, LePechoux C, Van Houtte P. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol. 2018;127(1):1\u20135.","journal-title":"Radiother Oncol"},{"key":"15901_CR24","doi-asserted-by":"publisher","unstructured":"Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, K\u00fcsters A, et al. PET-Plan study group. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol. 2020;21(4):581\u2013592. https:\/\/doi.org\/10.1016\/S1470-2045(20)30013-9. Epub 12 Mar 2020. PMID: 32171429.","DOI":"10.1016\/S1470-2045(20)30013-9"},{"issue":"7","key":"15901_CR25","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1200\/JCO.19.01162","volume":"38","author":"JD Bradley","year":"2020","unstructured":"Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Koprowski CD, Olson MR, Meng J, Paulus R, Curran WJ Jr. Long-term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2020;38(7):706\u201314.","journal-title":"J Clin Oncol"},{"issue":"2","key":"15901_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"JD Bradley","year":"2015","unstructured":"Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr., Choy H. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187\u201399.","journal-title":"Lancet Oncol"},{"issue":"1","key":"15901_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","volume":"35","author":"SG Chun","year":"2017","unstructured":"Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, Bogart JA, Dobelbower MC, Bosch W, Galvin JM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Raben A, Augspurger ME, MacRae RM, Paulus R, Bradley JD. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35(1):56\u201362.","journal-title":"J Clin Oncol"},{"issue":"19","key":"15901_CR28","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1093\/jnci\/djr325","volume":"103","author":"WJ Curran Jr","year":"2011","unstructured":"Curran WJ Jr., Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, Movsas B, Wasserman T, Rosenthal SA, Gore E, Machtay M, Sause W, Cox JD. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011;103(19):1452\u201360.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"15901_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jtho.2022.09.004","volume":"18","author":"M Craddock","year":"2023","unstructured":"Craddock M, Nestle U, Koenig J, Schimek-Jasch T, Kremp S, Lenz S, Banfill K, Davey A, Price G, Salem A, Faivre-Finn C, van Herk M, McWilliam A. Cardiac function modifies the impact of heart base dose on survival: a voxel-wise analysis of patients with lung cancer from the PET-plan trial. J Thorac Oncol. 2023;18(1):57\u201366.","journal-title":"J Thorac Oncol"},{"key":"15901_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.radonc.2021.07.017","volume":"163","author":"E Gkika","year":"2021","unstructured":"Gkika E, Schimek-Jasch T, Kremp S, Lenz S, Stockinger M, Schaefer-Schuler A, Mix M, Kusters A, Tosch M, Hehr T, Eschmann SM, Bultel YP, Hass P, Fleckenstein J, Thieme AH, Dieckmann K, Miederer M, Holl G, Rischke HC, Adebahr S, Konig J, Binder H, Grosu AL, Nestle U. Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial. Radiother Oncol. 2021;163:32\u20138.","journal-title":"Radiother Oncol"},{"issue":"10","key":"15901_CR31","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1001\/jamaoncol.2021.3186","volume":"7","author":"P Iyengar","year":"2021","unstructured":"Iyengar P, Zhang-Velten E, Court L, Westover K, Yan Y, Lin MH, Xiong Z, Patel M, Rivera D, Chang J, Saunders M, Shivnani A, Lee A, Hughes R, Gerber D, Dowell J, Gao A, Heinzerling J, Li Y, Ahn C, Choy H, Timmerman R. Accelerated hypofractionated image-guided vs conventional radiotherapy for patients with Stage II\/III non-small cell lung cancer and poor performance status: a randomized clinical trial. JAMA Oncol. 2021;7(10):1497\u2013505.","journal-title":"JAMA Oncol"},{"issue":"17","key":"15901_CR32","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.ejca.2014.07.009","volume":"50","author":"J Maguire","year":"2014","unstructured":"Maguire J, Khan I, McMenemin R, O\u2019Rourke N, McNee S, Kelly V, Peedell C, Snee M. SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III non-small cell lung cancer and good performance status. Eur J Cancer. 2014;50(17):2939\u201349.","journal-title":"Eur J Cancer"},{"issue":"3","key":"15901_CR33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.radonc.2016.02.011","volume":"118","author":"I Walraven","year":"2016","unstructured":"Walraven I, van den Heuvel M, van Diessen J, Schaake E, Uyterlinde W, Aerts J, Koppe F, Codrington H, Kunst P, Dieleman E, van de Vaart P, Verheij M, Belderbos J. Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. Radiother Oncol. 2016;118(3):442\u20136.","journal-title":"Radiother Oncol"},{"key":"15901_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.radonc.2019.07.028","volume":"143","author":"JNA van Diessen","year":"2020","unstructured":"van Diessen JNA, Kwint M, Sonke JJ, Walraven I, Stam B, de Langen AJ, Knegjens J, Belderbos JSA. Safety and efficacy of reduced dose and margins to involved lymph node metastases in locally advanced NSCLC patients. Radiother Oncol. 2020;143:66\u201372.","journal-title":"Radiother Oncol"},{"key":"15901_CR35","doi-asserted-by":"publisher","first-page":"586449","DOI":"10.3389\/fonc.2020.586449","volume":"10","author":"T Eichkorn","year":"2020","unstructured":"Eichkorn T, Bozorgmehr F, Regnery S, Dinges LA, Kudak A, Bougatf N, Weber D, Christopoulos P, Muley T, Kobinger S, Konig L, Horner-Rieber J, Adeberg S, Heussel CP, Thomas M, Debus J, El Shafie RA. Consolidation immunotherapy after platinum-based chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer-cross-sectional study of eligibility and administration rates. Front Oncol. 2020;10:586449.","journal-title":"Front Oncol"},{"issue":"5","key":"15901_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.cllc.2021.01.017","volume":"22","author":"T Shintani","year":"2021","unstructured":"Shintani T, Kishi N, Matsuo Y, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Narabayashi M, Ishida Y, Sakamoto M, Fujishiro S, Katagiri T, Kim YH, Mizowaki T. Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab. Clin Lung Cancer. 2021;22(5):401\u201310.","journal-title":"Clin Lung Cancer"},{"issue":"1","key":"15901_CR37","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2006.09.005","volume":"43","author":"J Belderbos","year":"2007","unstructured":"Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, Price A, van Walree N, Legrand C, Dussenne S, Bartelink H, Giaccone G, Koning C, Eortc LCG, Group RT. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972\u201322973). Eur J Cancer. 2007;43(1):114\u201321.","journal-title":"Eur J Cancer"},{"issue":"17","key":"15901_CR38","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1016\/j.ejca.2014.08.019","volume":"50","author":"JG Scott","year":"2014","unstructured":"Scott JG, Fletcher AG, Maini PK, Anderson ARA, Gerlee P. A filter-flow perspective of haematogenous metastasis offers a non-genetic paradigm for personalised cancer therapy. Eur J Cancer. 2014;50(17):3068\u201375.","journal-title":"Eur J Cancer"},{"issue":"1","key":"15901_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijrobp.2018.01.046","volume":"101","author":"JJ Urbanic","year":"2018","unstructured":"Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE. Phase 1 study of accelerated hypofractionated radiation therapy with concurrent chemotherapy for stage III non-small cell lung cancer: CALGB 31102 (alliance). Int J Radiat Oncol Biol Phys. 2018;101(1):177\u201385.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"15901_CR40","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"JH O","year":"2016","unstructured":"O JH, Lodge MA, Wahl RL, Practical PERCIST. A simplified guide to PET response criteria in solid tumors 1.0. Radiology. 2016;280(2):576\u201384.","journal-title":"Radiology"},{"issue":"1","key":"15901_CR41","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(1):S122\u201350.","journal-title":"J Nucl Med"},{"key":"15901_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.radonc.2020.02.015","volume":"146","author":"C Xu","year":"2020","unstructured":"Xu C, Jin JY, Zhang M, Liu A, Wang J, Mohan R, Kong FS, Lin SH. The impact of the effective dose to immune cells on lymphopenia and survival of esophageal cancer after chemoradiotherapy. Radiother Oncol. 2020;146:180\u20136.","journal-title":"Radiother Oncol"},{"issue":"1","key":"15901_CR43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijrobp.2004.12.060","volume":"63","author":"O Chapet","year":"2005","unstructured":"Chapet O, Kong FM, Quint LE, Chang AC, Ten Haken RK, Eisbruch A, Hayman JA. CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan. Int J Radiat Oncol Biol Phys. 2005;63(1):170\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"15901_CR44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00066-011-0015-x","volume":"188","author":"N Hodapp","year":"2012","unstructured":"Hodapp N. The ICRU Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)]. Strahlenther Onkol. 2012;188(1):97\u20139.","journal-title":"Strahlenther Onkol"},{"issue":"11","key":"15901_CR45","doi-asserted-by":"publisher","first-page":"6512","DOI":"10.3390\/curroncol31110483","volume":"31","author":"AM Brade","year":"2024","unstructured":"Brade AM, Bahig H, Bezjak A, Juergens RA, Lynden C, Marcoux N, Melosky B, Schellenberg D, Snow S. Esophagitis and pneumonitis related to concurrent chemoradiation +\/- durvalumab consolidation in unresectable stage III non-small-cell lung cancer: risk assessment and management recommendations based on a modified delphi process. Curr Oncol. 2024;31(11):6512\u201335.","journal-title":"Curr Oncol"},{"issue":"7","key":"15901_CR46","first-page":"100197","volume":"2","author":"N Shaverdian","year":"2021","unstructured":"Shaverdian N, Offin M, Shepherd AF, Hellmann MD, Gomez DR, Chaft JE, Rimner A. association between the early discontinuation of durvalumab and poor survival in patients with stage III NSCLC. JTO Clin Res Rep. 2021;2(7):100197.","journal-title":"JTO Clin Res Rep"},{"key":"15901_CR47","doi-asserted-by":"publisher","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342\u20132350. https:\/\/doi.org\/10.1056\/NEJMoa1809697 Epub 2018 Sep 25. PMID: 30280658.","DOI":"10.1056\/NEJMoa1809697"},{"key":"15901_CR48","doi-asserted-by":"publisher","unstructured":"Jin JY, Hu C, Xiao Y, Zhang H, Paulus R, Ellsworth SG, et al. Higher Radiation Dose to the Immune Cells Correlates with Worse Tumor Control and Overall Survival in Patients with Stage III NSCLC: A Secondary Analysis of RTOG0617. Cancers (Basel). 2021;13(24):6193. https:\/\/doi.org\/10.3390\/cancers13246193. PMID: 34944813; PMCID: PMC8699524.","DOI":"10.3390\/cancers13246193"},{"key":"15901_CR49","doi-asserted-by":"publisher","unstructured":"Ladbury CJ, Rusthoven CG, Camidge DR, Kavanagh BD, Nath SK. Impact of Radiation Dose to the Host Immune System on Tumor Control and Survival for Stage III Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019;105(2):346\u2013355. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.05.064.\u00a0Epub 5 Jun 2019. PMID: 31175902.","DOI":"10.1016\/j.ijrobp.2019.05.064"},{"issue":"9618","key":"15901_CR50","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","volume":"371","author":"ST Group","year":"2008","unstructured":"Group ST, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098\u2013107.","journal-title":"Lancet"},{"key":"15901_CR51","doi-asserted-by":"crossref","unstructured":"Khan HM, Ramsey S, Shankaran V. Financial toxicity in cancer care: implications for clinical care and potential practice solutions. In: J Clin Oncol; 2023;2023. pp. 3051\u20133058.","DOI":"10.1200\/JCO.22.01799"},{"key":"15901_CR52","doi-asserted-by":"publisher","first-page":"8170428","DOI":"10.1155\/2019\/8170428","volume":"2019","author":"A Moore","year":"2019","unstructured":"Moore A, Stav I, Den RB, Gordon N, Sarfaty M, Neiman V, Rosenbaum E, Goldstein DA. The Financial impact of hypofractionated radiation for localized prostate cancer in the United States. J Oncol. 2019;2019:8170428.","journal-title":"J Oncol"},{"issue":"2","key":"15901_CR53","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1016\/j.prro.2020.09.010","volume":"11","author":"N Ohri","year":"2021","unstructured":"Ohri N, Halmos B, Bodner WR, Cheng H, Garg MK, Gucalp R, Guha C. Who benefits the most from adjuvant durvalumab after chemoradiotherapy for non-small cell lung cancer? an exploratory analysis. Pract Radiat Oncol. 2021;11(2):e172\u20139.","journal-title":"Pract Radiat Oncol"},{"issue":"8","key":"15901_CR54","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/nrc2444","volume":"8","author":"C Murdoch","year":"2008","unstructured":"Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618\u201331.","journal-title":"Nat Rev Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15901-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15901-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15901-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:14:25Z","timestamp":1781648065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15901-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15901"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15901-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved for all participating European Union centres under EU CT Number 2023-510506-41-00, with the Ethics Committee of the \u00c4rztekammer Nordrhein acting as the responsible ethics committee (reference no. 2023005). For Swiss participating centres, approval was granted by the Cantonal Ethics Committee Zurich under BASEC No. 2023\u2009\u2212\u200902008. Institutional review boards acknowledged the central ethics committee vote as required according to CTIS regulation, and all patients provided written informed consent prior to study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RES has received research grants from AstraZeneca related to the presented work, and honoraria and travel expenses from AstraZeneca, Accuray Inc., Novocure, Merck, and MSD outside of the presented work. MM reports compensation for scientific consulting by Novartis, Roche, Telix and Veraxa outside of the submitted work. FM has received an unrestricted research institutional grant from AstraZeneca not related to the present work; honoraria from AstraZeneca, Novartis, Roche, Lilly, Elekta, and Brainlab; and serves on the advisory boards of AstraZeneca and Novartis. PC has received research funding from AstraZeneca, Amgen, Boehringer Ingelheim, Merck, Novartis, Roche, and Takeda; speaker\u2019s honoraria from AstraZeneca, Gilead, Janssen, Merck, Novartis, Roche, Pfizer, Thermo Fisher, and Takeda; support for attending meetings from AstraZeneca, Eli Lilly, Daiichi Sankyo, Janssen, Gilead, Merck, Novartis, Pfizer, and Takeda; and personal fees for participation on advisory boards from AstraZeneca, Boehringer Ingelheim, Chugai, Janssen, Pfizer, Novartis, MSD, Takeda, and Roche, all outside the submitted work. MH reports compensation for scientific consulting by Merck Serono, MSD, BMS, AstraZeneca, Sanofi; travel expenses by Merck Serono, MSD, BMS, AstraZeneca, Sanofi; research funding by MSD and AstraZeneca; all outside of the submitted work. GSB is an employee of AstraZeneca who also provide funding for the presented work. JM is an employee of AstraZeneca who also provide funding for the presented work. SR has received research grants from AstraZeneca related to the presented work, and honoraria and travel expenses from AstraZeneca and onkowissen.de GmbH outside of the presented work. UN has received research grants from AstraZeneca related to the presented work and honoraria and travel expenses from AstraZeneca outside of the presented work. JW, EG, TSJ, MM, FB, FG, TH, RB, MS, MG, SHE and SHA report no conflict of interest relevant to the presented work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"494"}}